NYSEAMERICAN:MAIA MAIA Biotechnology Q4 2025 Earnings Report $1.34 -0.02 (-1.10%) As of 09:49 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings History MAIA Biotechnology EPS ResultsActual EPS-$0.08Consensus EPS -$0.13Beat/MissBeat by +$0.05One Year Ago EPSN/AMAIA Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMAIA Biotechnology Announcement DetailsQuarterQ4 2025Date3/23/2026TimeBefore Market OpensConference Call DateMonday, March 23, 2026Conference Call Time7:00AM ETUpcoming EarningsMAIA Biotechnology's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) MAIA Biotechnology Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)June 11, 2026 | theglobeandmail.comMAIA Biotechnology opens second US site for THIO-101 trialJune 11, 2026 | yahoo.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.June 16 at 1:00 AM | Priority Gold (Ad)MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion TrialJune 10, 2026 | globenewswire.comMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer TrialJune 4, 2026 | globenewswire.comMAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial ExpansionJune 3, 2026 | globenewswire.comSee More MAIA Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email. Email Address About MAIA BiotechnologyMAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications. The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions. Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.View MAIA Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?3 AI Stocks With Moats That Could Outlast Summer VolatilityViasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on Inflation Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
